MR imaging of middle cerebellar peduncle width: differentiation of multiple system atrophy from Parkinson disease.

PURPOSE To prospectively assess if middle cerebellar peduncle (MCP) atrophy, evaluated at magnetic resonance (MR) imaging, can help differentiate multiple system atrophy (MSA) from Parkinson disease (PD). MATERIALS AND METHODS All participants provided informed consent for participation in the study, which was approved by the institutional review board. Sixteen consecutive patients with MSA, 26 consecutive patients with PD, and 14 healthy control subjects were examined with MR imaging. Images were interpreted independently by two experienced neuroradiologists blinded to clinical information, who visually inspected the images for the presence or absence of putaminal atrophy, putaminal hypointensity, slitlike hyperintensity in the posterolateral margin of the putamen, brainstem atrophy, hyperintensity of the MCP, and cruciform hyperintensity of the pons. Measurements of MCP width on T1-weighted volumetric spoiled gradient-echo images were performed in all subjects. Differences in MCP width among the groups were evaluated by using the Kruskall-Wallis test, followed by the Mann-Whitney U test for multiple comparisons and Bonferroni correction. RESULTS All patients (mean age, 63.88 years; range, 55-72 years) with MSA had at least one of the features commonly observed in this disease on MR images, whereas control subjects (mean age, 66.93 years; range, 61-77 years) and all but one patient with PD (mean age, 65.31 years; range, 51-79 years) had normal MR images. The average MCP width was significantly smaller in patients with MSA (6.10 mm+/-1.18 [standard deviation]) than in those with PD (9.32 mm+/-0.77, P<.001) or control subjects (9.80 mm+/-0.66, P<.001). CONCLUSION Measurement of MCP width on MR images may be useful for distinguishing patients with MSA from those with PD.

[1]  T. Gasser,et al.  123I‐iodobenzamide‐SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism , 1992, Neurology.

[2]  J D Speelman,et al.  Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography. , 1993, Archives of neurology.

[3]  Carlo Colosimo,et al.  Multiple system atrophy , 2004, The Lancet Neurology.

[4]  C. Marsden,et al.  Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy , 1995, Annals of neurology.

[5]  D Petersen,et al.  Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[6]  F. Tison,et al.  Routine MRI for the differential diagnosis of Parkinson's disease, MSA, PSP, and CBD , 2003, Journal of Neural Transmission.

[7]  Richard S. J. Frackowiak,et al.  Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography , 1992, Annals of neurology.

[8]  Dorothee P Auer,et al.  T2*-weighted MRI differentiates multiple system atrophy from Parkinson’s disease , 2002, Neurology.

[9]  B. Drayer,et al.  Brain magnetic resonance imaging in multiple-system atrophy and Parkinson disease: a diagnostic algorithm. , 2002, Archives of neurology.

[10]  N P Quinn,et al.  Olivopontocerebellar pathology in multiple system atrophy , 1996, Movement disorders : official journal of the Movement Disorder Society.

[11]  D. Dickson,et al.  Multiple System Atrophy: A Sporadic Synucleinopathy , 1999, Brain pathology.

[12]  C. Good,et al.  Differentiation of atypical parkinsonian syndromes with routine MRI , 2000, Neurology.

[13]  C Kremser,et al.  Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD , 2002, Neurology.

[14]  S. Nakamura,et al.  Characteristic magnetic resonance imaging findings in Machado-Joseph disease. , 1998, Archives of neurology.

[15]  A J Lees,et al.  Clinical usefulness of magnetic resonance imaging in multiple system atrophy , 1998, Journal of neurology, neurosurgery, and psychiatry.

[16]  R A Zimmerman,et al.  Olivopontocerebellar atrophy: MR diagnosis and relationship to multisystem atrophy. , 1990, Radiology.

[17]  B. Snow,et al.  Criteria for diagnosing Parkinson's disease , 1992, Annals of neurology.

[18]  M. Skalej,et al.  Magnetic resonance imaging–based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy , 1999, Annals of neurology.

[19]  L Solymosi,et al.  Measurement of the midbrain diameter on routine magnetic resonance imaging: a simple and accurate method of differentiating between Parkinson disease and progressive supranuclear palsy. , 2001, Archives of neurology.

[20]  N P Quinn,et al.  Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. , 1994, Brain : a journal of neurology.

[21]  D J Brooks,et al.  Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[22]  Osamu Onodera,et al.  Quantitative evaluation of brainstem involvement in multiple system atrophy by diffusion-weighted MR imaging , 2004, Journal of Neurology.

[23]  I Litvan,et al.  Consensus statement on the diagnosis of multiple system atrophy , 1998, Journal of the Neurological Sciences.